| ||||
Public Act 103-0245 | ||||
| ||||
| ||||
AN ACT concerning criminal law.
| ||||
Be it enacted by the People of the State of Illinois,
| ||||
represented in the General Assembly:
| ||||
Section 5. The Illinois Controlled Substances Act is | ||||
amended by changing Section 204 as follows: | ||||
(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | ||||
Sec. 204. (a) The controlled substances listed in this | ||||
Section are
included in Schedule I. | ||||
(b) Unless specifically excepted or unless listed in | ||||
another
schedule, any of the following opiates, including | ||||
their isomers,
esters, ethers, salts, and salts of isomers, | ||||
esters, and ethers,
whenever the existence of such isomers, | ||||
esters, ethers and salts is
possible within the specific | ||||
chemical designation: | ||||
(1) Acetylmethadol; | ||||
(1.1) Acetyl-alpha-methylfentanyl | ||||
(N-[1-(1-methyl-2-phenethyl)-
| ||||
4-piperidinyl]-N-phenylacetamide); | ||||
(2) Allylprodine; | ||||
(3) Alphacetylmethadol, except
| ||||
levo-alphacetylmethadol (also known as levo-alpha-
| ||||
acetylmethadol, levomethadyl acetate, or LAAM); | ||||
(4) Alphameprodine; |
(5) Alphamethadol; | ||
(6) Alpha-methylfentanyl
| ||
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| ||
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| ||
propanilido) piperidine; | ||
(6.1) Alpha-methylthiofentanyl
| ||
(N-[1-methyl-2-(2-thienyl)ethyl-
| ||
4-piperidinyl]-N-phenylpropanamide); | ||
(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | ||
(7.1) PEPAP
| ||
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | ||
(8) Benzethidine; | ||
(9) Betacetylmethadol; | ||
(9.1) Beta-hydroxyfentanyl
| ||
(N-[1-(2-hydroxy-2-phenethyl)-
| ||
4-piperidinyl]-N-phenylpropanamide); | ||
(10) Betameprodine; | ||
(11) Betamethadol; | ||
(12) Betaprodine; | ||
(13) Clonitazene; | ||
(14) Dextromoramide; | ||
(15) Diampromide; | ||
(16) Diethylthiambutene; | ||
(17) Difenoxin; | ||
(18) Dimenoxadol; | ||
(19) Dimepheptanol; |
(20) Dimethylthiambutene; | ||
(21) Dioxaphetylbutyrate; | ||
(22) Dipipanone; | ||
(23) Ethylmethylthiambutene; | ||
(24) Etonitazene; | ||
(25) Etoxeridine; | ||
(26) Furethidine; | ||
(27) Hydroxpethidine; | ||
(28) Ketobemidone; | ||
(29) Levomoramide; | ||
(30) Levophenacylmorphan; | ||
(31) 3-Methylfentanyl
| ||
(N-[3-methyl-1-(2-phenylethyl)-
| ||
4-piperidyl]-N-phenylpropanamide); | ||
(31.1) 3-Methylthiofentanyl
| ||
(N-[(3-methyl-1-(2-thienyl)ethyl-
| ||
4-piperidinyl]-N-phenylpropanamide); | ||
(32) Morpheridine; | ||
(33) Noracymethadol; | ||
(34) Norlevorphanol; | ||
(35) Normethadone; | ||
(36) Norpipanone; | ||
(36.1) Para-fluorofentanyl
| ||
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| ||
4-piperidinyl]propanamide); | ||
(37) Phenadoxone; |
(38) Phenampromide; | ||
(39) Phenomorphan; | ||
(40) Phenoperidine; | ||
(41) Piritramide; | ||
(42) Proheptazine; | ||
(43) Properidine; | ||
(44) Propiram; | ||
(45) Racemoramide; | ||
(45.1) Thiofentanyl
| ||
(N-phenyl-N-[1-(2-thienyl)ethyl-
| ||
4-piperidinyl]-propanamide); | ||
(46) Tilidine; | ||
(47) Trimeperidine; | ||
(48) Beta-hydroxy-3-methylfentanyl (other name:
| ||
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| ||
N-phenylpropanamide); | ||
(49) Furanyl fentanyl (FU-F); | ||
(50) Butyryl fentanyl; | ||
(51) Valeryl fentanyl; | ||
(52) Acetyl fentanyl; | ||
(53) Beta-hydroxy-thiofentanyl; | ||
(54) 3,4-dichloro-N-[2-
| ||
(dimethylamino)cyclohexyl]-N-
| ||
methylbenzamide (U-47700); | ||
(55) 4-chloro-N-[1-[2-
| ||
(4-nitrophenyl)ethyl]-2-piperidinylidene]-
|
benzenesulfonamide (W-18); | ||
(56) 4-chloro-N-[1-(2-phenylethyl)
| ||
-2-piperidinylidene]-benzenesulfonamide (W-15); | ||
(57) acrylfentanyl (acryloylfentanyl). | ||
(c) Unless specifically excepted or unless listed in | ||
another
schedule, any of the following opium derivatives, its | ||
salts, isomers
and salts of isomers, whenever the existence of | ||
such salts, isomers and
salts of isomers is possible within | ||
the specific chemical designation: | ||
(1) Acetorphine; | ||
(2) Acetyldihydrocodeine; | ||
(3) Benzylmorphine; | ||
(4) Codeine methylbromide; | ||
(5) Codeine-N-Oxide; | ||
(6) Cyprenorphine; | ||
(7) Desomorphine; | ||
(8) Diacetyldihydromorphine (Dihydroheroin); | ||
(9) Dihydromorphine; | ||
(10) Drotebanol; | ||
(11) Etorphine (except hydrochloride salt); | ||
(12) Heroin; | ||
(13) Hydromorphinol; | ||
(14) Methyldesorphine; | ||
(15) Methyldihydromorphine; | ||
(16) Morphine methylbromide; | ||
(17) Morphine methylsulfonate; |
(18) Morphine-N-Oxide; | ||
(19) Myrophine; | ||
(20) Nicocodeine; | ||
(21) Nicomorphine; | ||
(22) Normorphine; | ||
(23) Pholcodine; | ||
(24) Thebacon. | ||
(d) Unless specifically excepted or unless listed in | ||
another
schedule, any material, compound, mixture, or | ||
preparation which contains
any quantity of the following | ||
hallucinogenic substances, or which
contains any of its salts, | ||
isomers and salts of isomers, whenever the
existence of such | ||
salts, isomers, and salts of isomers is possible
within the | ||
specific chemical designation (for the purposes of this
| ||
paragraph only, the term "isomer" includes the optical, | ||
position and
geometric isomers): | ||
(1) 3,4-methylenedioxyamphetamine
| ||
(alpha-methyl,3,4-methylenedioxyphenethylamine,
| ||
methylenedioxyamphetamine, MDA); | ||
(1.1) Alpha-ethyltryptamine
| ||
(some trade or other names: etryptamine;
| ||
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| ||
3-(2-aminobutyl)indole; a-ET; and AET); | ||
(2) 3,4-methylenedioxymethamphetamine (MDMA); | ||
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
| ||
(also known as: N-ethyl-alpha-methyl-
|
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| ||
and MDEA); | ||
(2.2) N-Benzylpiperazine (BZP); | ||
(2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | ||
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | ||
(4) 3,4,5-trimethoxyamphetamine (TMA); | ||
(5) (Blank); | ||
(6) Diethyltryptamine (DET); | ||
(7) Dimethyltryptamine (DMT); | ||
(7.1) 5-Methoxy-diallyltryptamine; | ||
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | ||
(9) Ibogaine (some trade and other names:
| ||
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| ||
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| ||
indole; Tabernanthe iboga); | ||
(10) Lysergic acid diethylamide; | ||
(10.1) Salvinorin A; | ||
(10.5) Salvia divinorum (meaning all parts of the | ||
plant presently classified
botanically as Salvia | ||
divinorum, whether growing or not, the
seeds thereof, any | ||
extract from any part of that plant, and every compound,
| ||
manufacture, salts, isomers, and salts of
isomers whenever | ||
the existence of such salts, isomers, and salts of
isomers | ||
is possible within the specific chemical designation, | ||
derivative, mixture, or preparation of that plant, its
| ||
seeds or extracts);
|
(11) 3,4,5-trimethoxyphenethylamine (Mescaline); | ||
(12) Peyote (meaning all parts of the plant presently | ||
classified
botanically as Lophophora williamsii
Lemaire, | ||
whether growing or not, the
seeds thereof, any extract | ||
from any part of that plant, and every compound,
| ||
manufacture, salts, derivative, mixture, or preparation of | ||
that plant, its
seeds or extracts); | ||
(13) N-ethyl-3-piperidyl benzilate (JB 318); | ||
(14) N-methyl-3-piperidyl benzilate; | ||
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| ||
(also known as N-hydroxy-alpha-methyl-
| ||
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | ||
(15) Parahexyl; some trade or other names:
| ||
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| ||
dibenzo (b,d) pyran; Synhexyl; | ||
(16) Psilocybin; | ||
(17) Psilocyn; | ||
(18) Alpha-methyltryptamine (AMT); | ||
(19) 2,5-dimethoxyamphetamine
| ||
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | ||
(20) 4-bromo-2,5-dimethoxyamphetamine
| ||
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| ||
4-bromo-2,5-DMA); | ||
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| ||
Some trade or other names: 2-(4-bromo-
| ||
2,5-dimethoxyphenyl)-1-aminoethane;
|
alpha-desmethyl DOB, 2CB, Nexus; | ||
(21) 4-methoxyamphetamine
| ||
(4-methoxy-alpha-methylphenethylamine;
| ||
paramethoxyamphetamine; PMA); | ||
(22) (Blank); | ||
(23) Ethylamine analog of phencyclidine.
| ||
Some trade or other names:
| ||
N-ethyl-1-phenylcyclohexylamine,
| ||
(1-phenylcyclohexyl) ethylamine,
| ||
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | ||
(24) Pyrrolidine analog of phencyclidine. Some trade | ||
or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | ||
PHP; | ||
(25) 5-methoxy-3,4-methylenedioxy-amphetamine; | ||
(26) 2,5-dimethoxy-4-ethylamphetamine
| ||
(another name: DOET); | ||
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| ||
(another name: TCPy); | ||
(28) (Blank); | ||
(29) Thiophene analog of phencyclidine (some trade
| ||
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| ||
2-thienyl analog of phencyclidine; TPCP; TCP); | ||
(29.1) Benzothiophene analog of phencyclidine. Some | ||
trade or other names: BTCP or benocyclidine; | ||
(29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | ||
(30) Bufotenine (some trade or other names:
|
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| ||
3-(2-dimethylaminoethyl)-5-indolol;
| ||
5-hydroxy-N,N-dimethyltryptamine;
| ||
N,N-dimethylserotonin; mappine); | ||
(31) (Blank); | ||
(32) (Blank); | ||
(33) (Blank); | ||
(34) (Blank); | ||
(34.5) (Blank); | ||
(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | ||
(2-methyloctan-2-yl)-6a,7, | ||
10,10a-tetrahydrobenzo[c]chromen-1-ol | ||
Some trade or other names: HU-210; | ||
(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | ||
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | ||
tetrahydrobenzo[c]chromen-1-ol, its isomers, | ||
salts, and salts of isomers; Some trade or other | ||
names: HU-210, Dexanabinol; | ||
(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | ||
6,6-dimethyl-3-(2-methyloctan-2-yl)- | ||
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | ||
Some trade or other names: HU-211; | ||
(37) (Blank); | ||
(38) (Blank); | ||
(39) (Blank); | ||
(40) (Blank); |
(41) (Blank); | ||
(42) Any compound structurally derived from | ||
3-(1-naphthoyl)indole or | ||
1H-indol-3-yl-(1-naphthyl)methane by substitution at the | ||
nitrogen atom of the indole ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl whether or not further substituted | ||
in the indole ring to any extent, whether or not | ||
substituted in the naphthyl ring to any extent. Examples | ||
of this structural class include, but are not limited to, | ||
JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | ||
(43) Any compound structurally derived from | ||
3-(1-naphthoyl)pyrrole by substitution at the nitrogen | ||
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
in the pyrrole ring to any extent, whether or not | ||
substituted in the naphthyl ring to any extent. Examples | ||
of this structural class include, but are not limited to, | ||
JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | ||
(44) Any compound structurally derived from | ||
1-(1-naphthylmethyl)indene by substitution at the | ||
3-position of the indene ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl whether or not further substituted | ||
in the indene ring to any extent, whether or not | ||
substituted in the naphthyl ring to any extent. Examples | ||
of this structural class include, but are not limited to, | ||
JWH-176; | ||
(45) Any compound structurally derived from | ||
3-phenylacetylindole by substitution at the nitrogen atom | ||
of the indole ring with alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
in the indole ring to any extent, whether or not | ||
substituted in the phenyl ring to any extent. Examples of | ||
this structural class include, but are not limited to, | ||
JWH-167, JWH-250, JWH-251, and RCS-8; | ||
(46) Any compound structurally derived from | ||
2-(3-hydroxycyclohexyl)phenol by substitution at the | ||
5-position of the phenolic ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not substituted in the | ||
cyclohexyl ring to any extent. Examples of this structural | ||
class include, but are not limited to, CP 47, 497 and its | ||
C8 homologue (cannabicyclohexanol); | ||
(46.1) Any compound structurally derived from |
3-(benzoyl) indole with substitution at the nitrogen atom | ||
of the indole ring by an alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl group whether or not further | ||
substituted in the indole ring to any extent and whether | ||
or not substituted in the phenyl ring to any extent. | ||
Examples of this structural class include, but are not | ||
limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN | ||
48,098), and RCS-4; | ||
(47) (Blank); | ||
(48) (Blank); | ||
(49) (Blank); | ||
(50) (Blank); | ||
(51) (Blank); | ||
(52) (Blank); | ||
(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. | ||
Some trade or other names: 2C-T-7; | ||
(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some | ||
trade or other names: 2C-E; | ||
(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some | ||
trade or other names: 2C-D; | ||
(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some | ||
trade or other names: 2C-C; | ||
(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade | ||
or other names: 2C-I; |
(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some | ||
trade or other names: 2C-T-2; | ||
(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. | ||
Some trade or other names: 2C-T-4; | ||
(53.7) 2,5-dimethoxyphenethylamine. Some trade or | ||
other names: 2C-H; | ||
(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some | ||
trade or other names: 2C-N; | ||
(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some | ||
trade or other names: 2C-P; | ||
(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. | ||
Some trade or other names: 2C-G; | ||
(53.11) The N-(2-methoxybenzyl) derivative of any 2C | ||
phenethylamine referred to in subparagraphs (20.1), (53), | ||
(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | ||
(53.8), (53.9), and (53.10) including, but not limited to, | ||
25I-NBOMe and 25C-NBOMe; | ||
(54) 5-Methoxy-N,N-diisopropyltryptamine; | ||
(55) (Blank); | ||
(56) (Blank); | ||
(57) (Blank); | ||
(58) (Blank); | ||
(59) 3-cyclopropoylindole with substitution at the | ||
nitrogen atom of the indole ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indole ring to any extent, whether or not | ||
substituted on the cyclopropyl ring to any extent: | ||
including, but not limited to, XLR11, UR144, FUB-144; | ||
(60) 3-adamantoylindole with substitution at the | ||
nitrogen atom of the indole ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indole ring to any extent, whether or not | ||
substituted on the adamantyl ring to any extent: | ||
including, but not limited to, AB-001; | ||
(61) N-(adamantyl)-indole-3-carboxamide with | ||
substitution at the nitrogen atom of the indole ring by | ||
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||
cycloalkylethyl, aryl halide, alkyl aryl halide, | ||
1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indole ring to any extent, whether or not | ||
substituted on the adamantyl ring to any extent: | ||
including, but not limited to, APICA/2NE-1, STS-135; | ||
(62) N-(adamantyl)-indazole-3-carboxamide with | ||
substitution at a nitrogen atom of the indazole ring by | ||
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||
cycloalkylethyl, aryl halide, alkyl aryl halide, | ||
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indazole ring to any extent, whether or not | ||
substituted on the adamantyl ring to any extent: | ||
including, but not limited to, AKB48, 5F-AKB48; | ||
(63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | ||
with substitution at the nitrogen atom of the indole ring | ||
by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | ||
cycloalkylethyl, aryl halide, alkyl aryl halide, | ||
1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indole ring to any extent, whether or not | ||
substituted on the quinoline ring to any extent: | ||
including, but not limited to, PB22, 5F-PB22, FUB-PB-22; | ||
(64) 3-(1-naphthoyl)indazole with substitution at the | ||
nitrogen atom of the indazole ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | ||
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indazole ring to any extent, whether or not | ||
substituted on the naphthyl ring to any extent: including, | ||
but not limited to, THJ-018, THJ-2201; | ||
(65) 2-(1-naphthoyl)benzimidazole with substitution | ||
at the nitrogen atom of the benzimidazole ring by alkyl, | ||
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | ||
aryl halide, alkyl aryl halide, | ||
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the benzimidazole ring to any extent, whether or not | ||
substituted on the naphthyl ring to any extent: including, | ||
but not limited to, FUBIMINA; | ||
(66) | ||
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | ||
3-carboxamide with substitution on the nitrogen atom of | ||
the indazole ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indazole ring to any extent: including, but not | ||
limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | ||
(67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | ||
indazole-3-carboxamide with substitution on the nitrogen | ||
atom of the indazole ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indazole ring to any extent: including, but not | ||
limited to, ADB-PINACA, ADB-FUBINACA; | ||
(68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | ||
indole-3-carboxamide with substitution on the nitrogen | ||
atom of the indole ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indole ring to any extent: including, but not | ||
limited to, ADBICA, 5F-ADBICA; | ||
(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | ||
3-carboxamide with substitution on the nitrogen atom of | ||
the indole ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indole ring to any extent: including, but not | ||
limited to, ABICA, 5F-ABICA; | ||
(70) Methyl 2-(1H-indazole-3-carboxamido)-3- | ||
methylbutanoate with substitution on the nitrogen atom of | ||
the indazole ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted | ||
on the indazole ring to any extent: including, but not | ||
limited to, AMB, 5F-AMB; | ||
(71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | ||
dimethylbutanoate with substitution on the nitrogen
atom | ||
of the indazole ring by alkyl, haloalkyl, alkenyl,
| ||
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further substituted
| ||
on the indazole ring to any extent: including, but not
|
limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | ||
(72) Methyl 2-(1H-indole-3-carboxamido)-3- | ||
methylbutanoate with substitution on the nitrogen atom
of | ||
the indole ring by alkyl, haloalkyl, alkenyl,
| ||
cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl,
or | ||
2-(4-morpholinyl)ethyl, whether or not further
substituted | ||
on the indazole ring to any extent:
including, but not | ||
limited to, MMB018, MMB2201,
and AMB-CHMICA; | ||
(73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | ||
dimethylbutanoate with substitution
on the nitrogen atom | ||
of the indole ring by alkyl,
haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl,
whether or not further substituted | ||
on the
indazole ring to any extent: including, but
not | ||
limited to, MDMB-CHMICA; | ||
(74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | ||
indazole-3-carboxamide with
substitution on the nitrogen | ||
atom of the indazole
ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl | ||
halide,
1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl, whether or not further
substituted | ||
on the indazole ring to any
extent: including, but not | ||
limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; | ||
(75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- |
3-carboxamide with substitution on
the nitrogen atom of | ||
the indole ring by alkyl,
haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | ||
halide, 1-(N-methyl-2-piperidinyl)methyl, or | ||
2-(4-morpholinyl)ethyl,
whether or not further substituted | ||
on the indazole
ring to any extent: including, but not | ||
limited to,
APP-PICA and 5-fluoro-APP-PICA; | ||
(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | ||
4-AcO-DMT; | ||
(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | ||
name 5-MeO-MIPT; | ||
(78) 4-hydroxy Diethyltryptamine (4-HO-DET); | ||
(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | ||
(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | ||
(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
| ||
(4-HO-MiPT); | ||
(82) Fluorophenylpiperazine; | ||
(83) Methoxetamine; | ||
(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | ||
ethcathinone). | ||
(e) Unless specifically excepted or unless listed in | ||
another
schedule, any material, compound, mixture, or | ||
preparation which contains
any quantity of the following | ||
substances having a depressant effect on
the central nervous | ||
system, including its salts, isomers, and salts of
isomers | ||
whenever the existence of such salts, isomers, and salts of
|
isomers is possible within the specific chemical designation: | ||
(1) mecloqualone; | ||
(2) methaqualone; and | ||
(3) gamma hydroxybutyric acid. | ||
(f) Unless specifically excepted or unless listed in | ||
another schedule,
any material, compound, mixture, or | ||
preparation which contains any quantity
of the following | ||
substances having a stimulant effect on the central nervous
| ||
system, including its salts, isomers, and salts of isomers: | ||
(1) Fenethylline; | ||
(2) N-ethylamphetamine; | ||
(3) Aminorex (some other names:
| ||
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| ||
4-5-dihydro-5-phenyl-2-oxazolamine) and its
| ||
salts, optical isomers, and salts of optical isomers; | ||
(4) Methcathinone (some other names:
| ||
2-methylamino-1-phenylpropan-1-one;
| ||
Ephedrone; 2-(methylamino)-propiophenone;
| ||
alpha-(methylamino)propiophenone; N-methylcathinone;
| ||
methycathinone; Monomethylpropion; UR 1431) and its
| ||
salts, optical isomers, and salts of optical isomers; | ||
(5) Cathinone (some trade or other names:
| ||
2-aminopropiophenone; alpha-aminopropiophenone;
| ||
2-amino-1-phenyl-propanone; norephedrone); | ||
(6) N,N-dimethylamphetamine (also known as:
| ||
N,N-alpha-trimethyl-benzeneethanamine;
|
N,N-alpha-trimethylphenethylamine); | ||
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| ||
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | ||
(8) 3,4-Methylenedioxypyrovalerone (MDPV); | ||
(9) Halogenated amphetamines and
| ||
methamphetamines - any compound derived from either
| ||
amphetamine or methamphetamine through the substitution
| ||
of a halogen on the phenyl ring, including, but not
| ||
limited to, 2-fluoroamphetamine, 3-
| ||
fluoroamphetamine and 4-fluoroamphetamine; | ||
(10) Aminopropylbenzofuran (APB):
| ||
including 4-(2-Aminopropyl) benzofuran, 5-
| ||
(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| ||
benzofuran, and 7-(2-Aminopropyl) benzofuran; | ||
(11) Aminopropyldihydrobenzofuran (APDB):
| ||
including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| ||
5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| ||
6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| ||
and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | ||
(12) Methylaminopropylbenzofuran
| ||
(MAPB): including 4-(2-methylaminopropyl)
| ||
benzofuran, 5-(2-methylaminopropyl)benzofuran,
| ||
6-(2-methylaminopropyl)benzofuran
| ||
and 7-(2-methylaminopropyl)benzofuran. | ||
(g) Temporary listing of substances subject to emergency | ||
scheduling.
Any material, compound, mixture, or preparation |
that contains any quantity
of the following substances: | ||
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| ||
(benzylfentanyl), its optical isomers, isomers, salts,
and | ||
salts of isomers; | ||
(2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- | ||
phenylpropanamide (thenylfentanyl),
its optical isomers, | ||
salts, and salts of isomers. | ||
(h) Synthetic cathinones. Unless specifically excepted, | ||
any chemical compound which is not approved by the United | ||
States Food and Drug Administration or, if approved, is not | ||
dispensed or possessed in accordance with State or federal | ||
law, not including bupropion, structurally derived from | ||
2-aminopropan-1-one by substitution at the 1-position with | ||
either phenyl, naphthyl, or thiophene ring systems, whether or | ||
not the compound is further modified in one or more of the | ||
following ways: | ||
(1) by substitution in the ring system to any extent | ||
with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | ||
halide substituents, whether or not further substituted in | ||
the ring system by one or more other univalent | ||
substituents. Examples of this class include, but are not | ||
limited to, 3,4-Methylenedioxycathinone (bk-MDA); | ||
(2) by substitution at the 3-position with an acyclic | ||
alkyl substituent. Examples of this class include, but are | ||
not limited to, 2-methylamino-1-phenylbutan-1-one | ||
(buphedrone); or |
(3) by substitution at the 2-amino nitrogen atom with | ||
alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by | ||
inclusion of the 2-amino nitrogen atom in a cyclic | ||
structure. Examples of this class include, but are not | ||
limited to, Dimethylcathinone, Ethcathinone, and | ||
a-Pyrrolidinopropiophenone (a-PPP); or | ||
Any other synthetic cathinone which is not approved by the | ||
United States Food and Drug Administration or, if approved, is | ||
not dispensed or possessed in accordance with State or federal | ||
law. | ||
(i) Synthetic cannabinoids or piperazines. Any synthetic | ||
cannabinoid or piperazine which is not approved by the United | ||
States Food and Drug Administration or, if approved, which is | ||
not dispensed or possessed in accordance with State and | ||
federal law. | ||
(j) Unless specifically excepted or listed in another | ||
schedule, any chemical compound which is not approved by the | ||
United States Food and Drug Administration or, if approved, is | ||
not dispensed or possessed in accordance with State or federal | ||
law, and is derived from the following structural classes and | ||
their salts: | ||
(1) Benzodiazepine class: A fused 1,4-diazepine and | ||
benzene ring structure with a phenyl connected to the | ||
1,4-diazepine ring, with any substitution(s) or | ||
replacement(s) on the 1,4-diazepine or benzene ring, any | ||
substitution(s) on the phenyl ring, or any combination |
thereof. Examples of this class include but are not | ||
limited to: Clonazolam, Flualprazolam; or | ||
(2) Thienodiazepine class: A fused 1,4-diazepine and | ||
thiophene ring structure with a phenyl connected to the | ||
1,4-diazepine ring, with any substitution(s) or | ||
replacement(s) on the 1,4-diazepine or thiophene ring, any | ||
substitution(s) on the phenyl ring, or any combination | ||
thereof. Examples of this class include but are not | ||
limited to: Etizolam. | ||
(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | ||
100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. | ||
8-14-18 .)
|